Vertex (VERX – Research Report), the Technology sector company, was revisited by a Wall Street analyst today. Analyst Chris Quintero from ...

Morgan Stanley analyst Chris Quintero raised the firm’s price target on Vertex (VERX) to $62 from $50 and keeps an Overweight rating on the shares. The firm has greater conviction in Vertex being a ...

Vertex has reported phase 3 data on its near-approval pain drug candidate suzetrigine, shedding light on how the non-opioid painkiller combines with ibuprofen and why the prospect failed to match ...

Vertex's diverse pipeline, including Casgevy for SCD, suzetrigine for chronic pain, and the vanzacaftor triple for CF, positions it for growth despite launch challenges. Casgevy's complex ...

Vertex Pharmaceuticals is in the process of getting ... Further research and development (R&D) work, in the form of post-approval trials to clarify the niches in which it's most effective, will ...

So when a business like Vertex Pharmaceuticals (NASDAQ: VRTX) releases some new data on a potential blockbuster that could be just a few months away from being approved for sale, it's a big ...

Google Cloud is enabling general availability for its Vertex AI platform in addition to new features for its Healthcare Data Engine (HDE), the company announced in a press release this morning.

South Africans need to be in the know if we want to create a prosperous future. News24 has kept the country informed for 25 years, and we're about to enter a new chapter of fearless journalism. Join ...

Saudi Power Procurement Co. (SPPC) announced this week the shortlisted bidders for the final phase of the fifth round of the Saudi Arabian government's National Renewable Energy Program (NREP).

BMO Capital Markets analyst Evan Seigerman in a note to investors said the late-stage data for Vertex’s experimental non-opioid pain medication “reaffirms our confidence in the strength of suzetrigine ...

Derived prices are not provided by exchanges. They are derived by market makers in CFD OTC market and hence prices may not be accurate and may differ from the actual market price, meaning prices ...